Carol Mansfield

Carol Mansfield

Auto-generated profile, based on publicly available information

Carol Mansfield

RTI Health Solutions, Research Triangle Park, NC 27709, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2019 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
PDF file
CMCarol Mansfield
Carol Mansfield
DGDavid J. Gebben
David J. Gebben
JSJessie Sutphin
Jessie Sutphin
STStewart J. Tepper
Stewart J. Tepper
TSTodd J. Schwedt
Todd J. Schwedt
NSNeel Shah
Neel Shah

31 October 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
CMCarol Mansfield
Carol Mansfield
AMAnthony Masaquel
Anthony Masaquel
JSJessie Sutphin
Jessie Sutphin
EWElisa Weiss
Elisa Weiss
MGMeghan Gutierrez
Meghan Gutierrez
CRCarolina Reyes
Carolina Reyes
Key Points: CLL patients value higher PFS but would accept significant reductions in PFS to avoid serious adverse events. Adding even modest out-of-pocket costs changed treatment choices for hypothetical treatments, suggesting patients are sensitive to cost.

17 June 2017 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
KCKathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer
ALAlexander Liede
Alexander Liede
CMCarol A. Mansfield
Carol A. Mansfield
KMKelly A. Metcalfe
Kelly A. Metcalfe
MPMelanie A. Price
Melanie A. Price
D. Gareth EvansD. Gareth Evans
D. Gareth Evans
Purpose Unaffected women who carry BRCA1 or BRCA2 mutations face difficult choices about reducing their breast cancer risk. Understanding their treatment preferences could help us improve patient counseling and inform drug trials. The objective was to explore preferences for various risk-reducing options among women with germline BRCA1/2 mutations using a discrete-choice experiment survey and to compare expressed preferences with actual behaviors. Methods A discrete-choice experiment survey was designed wherein women choose between hypothetical treatments to reduce breast cancer risk. The hypothetical treatments were characterized by the extent of breast cancer risk reduction, treatment duration, impact on fertility, hormone levels, risk of uterine cancer, and ease and mode of administration. Data were analyzed using a random-parameters logit model. Women were also asked to express their preference between surgical and chemoprevention options and to report on their actual risk-reduction actions. Women aged 25–55 years with germline BRCA1/2 mutations who were unaffected with breast or ovarian cancer were recruited through research registries at five clinics and a patient advocacy group. Results Between January 2015 and March 2016, 622 women completed the survey. Breast cancer risk reduction was the most important consideration expressed, followed by maintaining fertility. Among the subset of women who wished to have children in future, the ability to maintain fertility was the most important factor, followed by the extent of risk reduction. Many more women said they would take a chemoprevention drug than had actually taken chemoprevention. Conclusions Women with BRCA1/2 mutations indicated strong preferences for breast cancer risk reduction and maintaining fertility. The expressed desire to have a safe chemoprevention drug available to them was not met by current chemoprevention options.

9 May 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
RPRyan S. Paquin
Ryan S. Paquin
RFRyan Fischer
Ryan Fischer
CMCarol Mansfield
Carol Mansfield
BMBrennan Mange
Brennan Mange
KBKatherine Beaverson
Katherine Beaverson
HPHolly Landrum Peay
Holly Landrum Peay
Several gene therapy trials for Duchenne muscular dystrophy initiated in 2018. Trial decision making is complicated by non-curative, time-limited benefits; the progressive, fatal course; and high unmet needs. Here, caregivers and patients prioritize factors influencing decision making regarding participation in early-phase gene therapy trials. We conducted a best-worst scaling experiment among U.S. caregivers and adults with Duchenne (N = 274). Participants completed 11 choice sets, choosing features they cared about most and least when deciding whether to participate in a hypothetical gene therapy trial. We analyzed the data using sequential conditional logistic regression. Participants prioritized improved muscle function in trial decision making. Concerns about participation limiting later use of gene transfer and editing were also important, as were improved lung and heart function. Low risk of death fell near the middle. Participants cared least about muscle biopsies and potential for randomization to placebo. Adults with Duchenne and caregivers of non-ambulatory children significantly prioritized improved lung function compared to caregivers of ambulatory children. Our data demonstrate prioritization of anticipated benefits and opportunity costs relative to potential harms and procedures in gene therapy trial decision making. Such data inform protocol development, education and advocacy efforts, and informed consent.

1 July 2017 in International Journal of MS Care
Verified
Journal Article
Closed access
CMCarol Mansfield
Carol Mansfield
NTNina Thomas
Nina Thomas
DGDavid Gebben
David Gebben
MLMaria Lucas
Maria Lucas
AHA. Brett Hauber
A. Brett Hauber
Background: The growing number of treatments for relapsing multiple sclerosis (MS) provides opportunities to consider patient preferences in treatment decisions. Methods: We designed a Web-based, discrete-choice experiment survey to analyze treatment preferences in patients with relapsing-remitting MS (RRMS). The survey presented hypothetical MS treatments defined by six attributes: risk of MS progression, time between relapses, risk of serious infection, treatment-related flu-like symptoms and gastrointestinal symptoms, and route and frequency of administration. Preference weights estimated with random-parameters logit were used to calculate importance scores and preference shares among three pairs of subsamples. Results: Patients with a self-reported physician diagnosis of RRMS (N = 301) completed the survey: 56% rated their disability level as normal or mild; 43% currently used a self-injectable treatment. Respondents with normal or mild disability levels placed greater weight on avoiding injections with flu-like symptoms and risk of progression, whereas patients with worse disability placed greater weight on reducing risk of progression and risk of serious infection. Patients taking injectables placed the most weight on risk of progression and risk of serious infection, whereas respondents not taking injectables placed the most weight on route and frequency of administration. Differences in preferences between subgroups were significant (P < .05). The presence of common adverse events associated with daily pills and injectables altered predicted preferences for route of administration. Conclusions: Preferences of patients with RRMS varied depending on current treatment and disability level, especially regarding mode of administration. Considering patient preferences for treatment features may lead to higher treatment satisfaction and adherence.

9 May 2018 in The Patient - Patient-Centered Outcomes Research
Verified
Journal Article
Closed access
PDF file
CMCarol Mansfield
Carol Mansfield
DEDonatus U. Ekwueme
Donatus U. Ekwueme
FTFlorence K. L. Tangka
Florence K. L. Tangka
DBDerek S. Brown
Derek S. Brown
JSJudith Lee Smith
Judith Lee Smith
BHBrett Hauber
Brett Hauber